2013
DOI: 10.1007/s00259-013-2526-4
|View full text |Cite
|
Sign up to set email alerts
|

Erratum to: Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthma

Abstract: The names of the first two authors of this article were rendered wrongly; their correct names are given here.The online version of the original article can be found at http://dx

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
7
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(7 citation statements)
references
References 0 publications
0
7
0
Order By: Relevance
“…There is sparse information regarding the safety of regadenoson for myocardial stress testing in Europe, with only one large report (16) and two minor reports published (17,18). At our institution, we introduced regadenoson for MPI stress testing in early 2013.…”
Section: Introductionmentioning
confidence: 87%
“…There is sparse information regarding the safety of regadenoson for myocardial stress testing in Europe, with only one large report (16) and two minor reports published (17,18). At our institution, we introduced regadenoson for MPI stress testing in early 2013.…”
Section: Introductionmentioning
confidence: 87%
“…Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patients [1] . It is characterized by inflammation of the deep lung and pulmonary hypoxemia.…”
Section: Introductionmentioning
confidence: 99%
“…This effect may be particularly relevant to some diseases, like chronic obstructive pulmonary disease (COPD) and asthma, both of which involve major inflammatory mechanisms, as well as to acute lung trauma. The efficacy of A 2A receptor agonists has indeed been demonstrated in preclinical models of these diseases (Bonneau et al 2006;Fozard et al 2002;LaPar et al 2011), and these drugs are currently under clinical evaluation, though with inconsistent results (Salgado Garcia et al 2014;Trevethick et al 2008) Adenosine A 2A receptors also regulate kidney physiology, by modulating the dilation of efferent arterioles, renal blood flow, and glomerular filtration rate (Al Mashhadi et al 2009;Carlström et al 2011;Levens et al 1991), as well as by influencing renal inflammation (Awad et al 2006;Garcia et al 2011;Okusa et al 1999). Finally, adenosine A 2A receptors have been suggested to participate in other physiopathological functions, such as ocular hemodynamics and protection from ischemic retinal damage (Zhong et al 2013), wound healing (Katebi et al 2008;Squadrito et al 2014), inflammation in experi-mental models of arthritis (Mazzon et al 2011), and tumour growth (Kalhan et al 2012;Montinaro et al 2013).…”
Section: Peripheral Effects Of Adenosine a 2a Receptorsmentioning
confidence: 96%